Polyhexamethylene Biguanide (PHMB): An Addendum to Current Topical Antimicrobials
- 0 Comments
- 12147 reads
BWD-PHMB pads (XCell Cellulose Wound Dressing–Antimicrobial) measuring 3.5-in x 3.5-in were provided to 2 clinical sites and used as the primary dressing. Secondary dressings, including compression wraps (where indicated), were the standard of care for the facilities. Patients were chosen on an “as needed” basis and neither randomized nor controlled.
The 2 sites evaluated a total of 12 patients with 26 wounds of various etiologies including venous stasis ulcers (12), diabetic (4), traumatic (8), vasculitic (1), and necrobiosis diabetica lipoidica (1). Eleven of the 12 patients were unresponsive to a silver impregnated or an iodine containing dressing in the 3–4 weeks prior to use of the BWD-PHMB dressing. In these cases the wound had either increased in size or failed to progress. One patient was treated directly with BWD-PHMB.
Swabs of the wound were taken to determine if bacterial colonization was the reason for the lack of response to previous dressings. Organisms were identified in the wounds of 8 patients prior to and after BWD-PHMB application. Systemic antibiotics were not given in conjunction with the use of BWD-PHMB to ensure bacterial reductions were solely due to the PHMB.
The organisms identified included methicillin-resistant Staphylococcus aureus (MRSA), Staphylococcus aureus, Pseudomonas aeruginosa, Proteus mirabilis, Diphtheroid gram-positive rods, beta hemolytic Streptococcus B, Enterobacter aerogenes, mixed skin flora, and Enterococcus sp. The most common was Staphylococcus (including MRSA) and Pseudomonas. Semiquantitative scores ranged from 0 to 4+ (0 represents no bacterial growth and 4+ represents the largest amount of bacterial growth on the culture). The various bacteria found in the wounds of all 8 patients and the relative abundance prior to and after application of the BWD-PHMB dressing are shown in Table 1.
Four patients (5 wounds) from 1 site were used strictly for the economic analysis below. Of the remaining 8, 1 patient (3 wounds) was lost to follow-up after 1 week of BWD-PHMB treatment. The remaining patients had BWD-PHMB applied over periods of 1 to 7 weeks. Results of the 8 patients demonstrated a decrease in wound size on average from 6.79 cm2 to 4.57 cm2 (42% reduction) in an average of 25 days (Table 2). Two of the wounds completely healed during the study, 13 improved, and 2 showed a slight increase in size.
1. Atiyeh BS, Ioannovich J, Al-Amm CA, El-Musa KA. Management of acute and chronic open wounds: the importance of moist environment in optimal wound healing. Curr Pharm Biotechnol. 2002;3(3):179–195.
2. Enoch S, Harding K. Wound bed preparation: the science behind the removal of barriers to healing. WOUNDS. 2003;15(7):213–229.
3. Falanga V. Wound bed preparation: future approaches. Ostomy Wound Manage. 2003;49(5A Suppl):30–33.
4. Schultz GS, Sibbald RG, Falanga V, et al. Wound bed preparation: a systematic approach to wound management. Wound Repair Regen. 2003;11(Suppl 1):S1–S28.
5. Junkin J. Failure to thrive in wounds: prevention and early intervention. Infect Control Resource. 2003;1(2):1–6.
6. Motta GJ, Milne CT, Corbett LQ. Impact of antimicrobial gauze on bacterial colonies in wounds that require packing. Ostomy Wound Manage. 2004;50(8):48–62.
7. Kingsley A. The wound infection continuum and its application to clinical practice. Ostomy Wound Manage. 2003;49(7A Suppl):1–7.
8. Ovington L. Bacterial toxins and wound healing. Ostomy Wound Manage. 2003;49(7A Suppl):8–12.
9. Sibbald RG. Topical antimicrobials. Ostomy Wound Manage. 2003;49(5A Suppl):14–18.
10. Mertz PM. Cutaneous biofilms: friend or foe? WOUNDS. 2003;15(5):129–132.
11. Stotts NA. Wound infection: diagnosis and management. In: Bryant RA, ed. Acute and Chronic Wounds: Nursing Management. 2nd ed. St. Louis, MO: Mosby: 2000:179–188.
12. Fraser JF, Bodman J, Sturgess R, Faoagali J, Kimble RM. An in-vitro study of the antimicrobial efficacy of a 1% silver sulphadiazine and 0.2% chlorhexidine digluconate cream, 1% silver sulfadiazine cream and a silver coated dressing. Burns. 2004;30(1):35–41.
13. Burrell RE. A scientific perspective on the use of topical silver preparations. Ostomy Wound Manage. 2003;49(5A Suppl):19–24.
14. Drosou A, Falabella A, Kirsner RS. Antiseptics on wounds: an area of controversy. WOUNDS. 2003;15(5):149–166.
15. Tambe SM, Sampath L, Modak SM. In-vitro evaluation of the risk of developing bacterial resistance to antiseptics and antibiotics used in medical devices. J Antimicrob Chemother. 2001;47(5):589–598.
16. Ovington LG. The truth about silver. Ostomy Wound Manage. 2004;50(9A Suppl):1S–10S.
17. Parsons D, Bowler PG, Myles V, Jones S. Silver antimicrobial dressings in wound management: a comparison of antibacterial, physical, and chemical characteristics. WOUNDS. 2005;17(8):222–232.
18. Fox CL, Modak SM. Mechanism of silver sulfadiazine action on burn wound infections. Antimicrob Agents Chemother. 1974:5(6):582–588.
19. Hohaus K, Vennewald I, Wollina U. Deep mycosis caused by Trichophyton mentagrophytes in a diabetic patient. Mycoses. 2003;46(8):355–357.
20. Thomas S, McCubbin P. A comparison of the antimicrobial effects of four silver-containing dressings on three organisms. J Wound Care. 2003;12(3):101–107.
21. Thomas S, McCubbin P. An in-vitro analysis of the antimicrobial properties of 10 silver-containing dressings. J Wound Care. 2003;12(8):305–308.
22. Jones S, Bowler PG, Walker M. Antimicrobial activity of silver-containing dressings is influenced by dressing conformability with a wound surface. WOUNDS. 2005;17(9):263–270.
23. Mertz PM, Oliveira-Gandia MF, Davis SC. The evaluation of a cadexomer iodine wound dressing on methicillin resistant Staphylococcus aureus (MRSA) in acute wounds. Dermatol Surg.1999;25(2):89–93.
24. Hansson C. The effects of cadexomer iodine paste in the treatment of venous leg ulcers compared with hydrocolloid dressing and paraffin gauze dressing. Cadexomer Iodine Study Group. Int J Dermatol. 1998;37(5):390–396.
25. Hughes R, Heaselgrave W, Kilvington S. Acanthamoeba polyphaga strain age and method of cyst production influence the observed efficacy of therapeutic agents and contact lens disinfectants. Antimicrob Agents Chemother. 2003;47(10):3080–3084.
26. Wright JB, Lam K, Olson ME, Burrell RE. Is antimicrobial efficacy sufficient? A question concerning the benefits of new dressings. WOUNDS. 2003;15(5):133–142.
27. Burger RM, Franco RJ, Drlica K. Killing Acanthamoebae with polyaminopropyl biguanide: quantitation and kinetics. Antimicrob Agents Chemother. 1994;38(4):886–888.
28. Hiti K, Walochnik J, Haller-Schober EM, Faschinger C, Aspock H. Viability of Acanthamoeba after exposure to a multipurpose disinfecting contact lens solution and two hydrogen peroxide systems. Br J Ophthalmol. 2002;86(2):144–146.
29. Barker J, Brown MR, Collier PJ, Farrell I, Gilbert P. Relationship between Legionella pneumophila and Acanthamoeba polyphaga: physiological status and susceptibility to chemical inactivation. Appl Env Microbiol. 1992;58(8):2420–2425.
30. Gilbert P, Das JR, Jones MV, Allison DG. Assessment of resistance towards biocides following the attachment of micro-organisms to, and growth on, surfaces. J Appl Microbiol. 2001;91(2):248–254.
31. Gilbert P, Pemberton D, Wilkinson DE. Synergism within polyhexamethylene biguanide biocide formulations. J Appl Bacteriol. 1990;69(4):593–598.
32. Zhou XF, Markx GH, Pethig R, Eastwood IM. Differentiation of viable and non-viable bacterial biofilms using electrorotation. Biochim Biophys Acta. 1995;1245(1):85–93.
33. Kramer A, Roth B, Müller G, Rudolph P, Klocker N. Influence of the antiseptic agents polyhexanide and octenidine on FL cells and on healing of experimental superficial aseptic wounds in piglets. A double-blind, randomized, stratified, controlled, parallel-group study. Skin Pharmacol Physiol. 2004;17(3):141–146.
34. Broxton P, Woodcock PM, Gilbert P. Binding of some polyhexamethylene biguanides to the cell envelope of Escherichia coli ATCC 8739. Microbios. 1984;41(163):15–22.
35. Broxton P, Woodcock PM, Heatley F, Gilbert P. Interaction of some polyhexamethylene biguanides and membrane phospholipids in Escherichia coli. J Appl Bacteriol. 1984;57(1):115–124.
36. Ikeda T, Ledwith A, Bamford CH, Hann RA. Interaction of a polymeric biguanide biocide with phospholipids membranes. Biochim Biophys Acta. 1984;769(1):57–66.
37. Yasuda K, Ohmizo C, Katsu T. Potassium and tetraphenylphosphonium ion-selective electrodes for monitoring changes in the permeability of bacterial outer and cytoplasmic membranes. J Microbiol Methods. 2003;54(1):111–115.
38. Kramer A, Behrens-Baumann W. Prophylactic use of topical anti-infectives in ophthalmology. Ophthalmologica. 1997;211(Suppl 1):68–76.
39. Rosin M, Welk A, Kocher T, Majic-Todt A, Kramer A, Pitten FA. The effect of a polyhexamethylene biguanide mouthrinse compared to an essential oil rinse and a chlorhexidine rinse on bacterial counts and 4-day plaque regrowth. J Clin Periodontol. 2002;29(5):392–399.
40. Petrou-Binder S. PHMB-containing antiseptics ‘may offer alternative’ to iodine perioperative agents, say researchers. Available at: http://www.escrs.org/eurotimes/April2003/phmb.asp.
41. Reitsma AM, Rodeheaver GT. Effectiveness of a new antimicrobial gauze dressing as a bacterial barrier. Mansfield, Mass: Tyco Healthcare Group LP; 2001:1–4.
42. Orr R, Eggleston T, Shelanski MV. Determination of the irritating and sensitizing propensities of Kerlix® A.M.D. antimicrobial gauze dressing on scarified human skin. Mansfield, Mass: Tyco Healthcare Group LP; 2001:1–4.
43. Frankel VH, Serafica GC, Damien CJ. Development and testing of a novel biosynthesized XCell for treating chronic wounds. Surg Technol Int. 2004;12:27–33.
44. Alvarez OA, Patel M, Booker J, Markowitz L. Effectiveness of a biocellulose wound dressing for the treatment of chronic venous leg ulcers: results of a single center randomized study involving 24 patients. WOUNDS. 2004;16(7):224–233.
45. Phillips T, Stanton B, Provan A, Lew R. A study of the impact of leg ulcers on quality of life: financial, social, and psychological implications. J Am Acad Dermatol. 1994;31(1):49–53.
46. Mulder GD. Cost-effective managed care: gel versus wet-to-dry for debridement. Ostomy Wound Manage. 1995;41(2):68–74.